go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd
Stonemason's Way, Rathfarnham, Dublin 16,
Telephone: +353 1 495 5000
Fax: +353 1 495 5105
Medical Information Direct Line: +353 1 800 244 255
Medical Information Facsimile: +353 1 495 5242
Summary of Product Characteristics last updated on medicines.ie: 16/03/2012
SPC IPV-Infanrix

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 16/03/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
Date of revision of text on the SPC:   13-Dec-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

Change to

 

 

Section 4.4 - Special warnings and precautions for use

 

Updated on 13/08/2010 and displayed until 16/03/2012
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 6.5 - Nature and contents of container
Date of revision of text on the SPC:   10-Aug-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



 

4.1       Therapeutic indications

Added the requirement:

‘who have previously received primary immunisation series against these diseases.’

 

4.3       Contraindications

Deleted the following statement:

IPV Infanrix should not be administered to subjects who experienced neurological complications (for convulsions or hypotonic-hyporesponsive episodes, see section 4.4) following previous immunisation with any of the antigens in the vaccine.

 

Updated contraindication warning regarding administration in children who have experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine, adding that:

In these circumstances pertussis vaccination should be discontinued and the vaccination should be continued with diphtheria-tetanus and polio vaccines.

 

4.4       Special warnings and precautions for use

Removed the requirement for a clinical examination prior to administration of the vaccine

 

Added the following statement regarding the risk-benefit of immunising in children with new onset or progression of a severe neurological disorder:

As for any vaccination, the risk-benefit of immunising with IPV Infanrix or deferring this vaccination should be weighed carefully in an infant or in a child suffering from a new onset or progression of a severe neurological disorder.

 

4.8       Undesirable effects

Revision of side effect listings from both Clinical trials and Post-marketing surveillance

 

4.9       Overdose

Previously no cases of over dose had been reported. This was updated with the addition of the following statement:

Cases of overdose have been reported during post-marketing surveillance. Adverse events, when reported, are not specific but similar to adverse events reported with normal vaccine administration.

 

6.5       Nature and contents of container

Added the optional 10 pack and statement that all packs may be presented with or without needles and a statement that not all pack sizes may be marketed.

 

 

Updated on 22/02/2010 and displayed until 13/08/2010
Reasons for adding or updating:
  • Change to section 6.1 - List of excipients
Date of revision of text on the SPC:   01-Jul-2008
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Section 6.1 - List of excipients

 

Removed the excipient 2-phenoxyethanol from the formulation.

Updated on 20/03/2007 and displayed until 22/02/2010
Reasons for adding or updating:
  • Improved electronic presentation
Updated on 15/08/2005 and displayed until 20/03/2007
Reasons for adding or updating:
  • New SPC for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine

Versions

 
16/03/2012 to Current
13/08/2010 to 16/03/2012
22/02/2010 to 13/08/2010
20/03/2007 to 22/02/2010
15/08/2005 to 20/03/2007
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo